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ABSTRACT 
The objective of the present work was to develop Gastro retentive dosage forms which would remain in the stomach and upper part or GIT for a 
prolonged period of time thereby maximizing the drug release at desired site within the time before GRDFs left the stomach and upper part of 
the GIT, has provoked a great deal of increased interest in the formulation of such drug as floating drug delivery systems. Levofloxacin, (BCS 
class I) is a fluoroquinolone anti-bacterial agent. The rationale for the formulation of floating matrix tablet are acidic solubility of levofloxacin, 
residence of Halicobactor pylori mainly in sub region of stomach and the overdosing associated adverse effect due to continuous intake of drug 
in acute infection. A simple visible spectrophotometric method was employed for the estimation of levofloxacin at 294 nm and Beer’s law is 
obeyed in the concentration range of 2-10 μg /ml. Floating matrix tablet of levofloxacin was prepared by direct compression method using 
different polymers like hydroxyl propyl methyl cellulose (HPMC K4) and carbopol 934 as matrix formation polymers, sodium bicarbonate and 
citric acid was used as gas generating agents. The FTIR spectra of the levofloxacin and other excipients alone and in combination show the 
compatibility of the drug and excipients. Six formulations of different polymer percentages were formulated (F1-F6). Pre-compression 
parameters were evaluated. The influence of matrix forming agents and binary mixtures of them on levofloxacin release was investigated. The 
formulated tablets were characterized by hardness, friability, thickness, weight variation and in vitro drug release. The formulated tablets had 
acceptable physicochemical characters. The data obtained from the in-vitro dissolution studies of optimized batch F4were fitted in different 
models. The optimized formulation F4 showed 99.25% drug content and swelling index of 79.85 %. Drug release mechanism was found to be 
first order kinetics. Levofloxacin floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic 
effect of the drug. 
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Floating drug delivery system (FDDS) shows buoyancy in 
stomach for extended time period thus offers extended 
gastric residence time for the dosage form ensuring optimal 
bioavailability (BA) 1. The residence time of the dosage form 
in the stomach depends upon various factors like pH, size of 
the dosage form, food intake, and biological factors which 
include age, body mass index, gender, posture, and diseased 
states (hepatic failure, diabetes, chrons disease). Other 
techniques for gastro retentive dosage forms involve 
swelling, mucoadhesion, sedimentation, microballoons 2,3 
and low density systems. Out of all systems available, the 
floating beads, floating tablets and floating microspheres 
have gained major importance. FDDS possess lower bulk 
density than the gastric fluid exerting buoyancy in the 
stomach leading to slow drug release in an extended manner 
before it reaches absorption window4. In this present 
formulation, dual benefits of buoyancy as well as sustained 
action are achieved with an intention to maintain the steady 
state of drug release5. Hydrophilic matrix system is one of 
the easiest approaches for developing modified and 
sustained release dosage forms. A polymer like hydroxyl 
propyl methyl cellulose (HPMC) function as a pH 
independent gelling agent and drug release is shown by 
swelling and erosion mechanism occurring simultaneously 
contributing to overall drug release6. Matrix system is the 
commonly used method for modulating the drug release7. 
The manufacture of matrix tablets by direct compression is 
cheaper, simpler process, broad regulatory acceptance, and 
allows flexibility in obtaining desirable release profiles8. 
Levofloxacin is a synthetic chemotherapeutic antibiotic of the 
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fluoroquinolone drug class and is used to treat severe or life-
threatening bacterial infections or bacterial infections that 
have failed to respond to other antibiotic classes9. 
Levofloxacin is a broad-spectrum antibiotic, inhibiting DNA 
gyrase, a type II topoisomerase, and topoisomerase IV, which 
is an enzyme necessary to separate replicated DNA, thereby 
inhibiting cell division10. The bioavailability of levofloxacin is 
above 99% with a plasma half-life of 6–8 h. It is freely soluble 
in pH 0.6 to 5.8 ranges. Above pH 5.8, the solubility increases 
rapidly to its maximum at pH 6.7 and above which the 
solubility decreases and reaches a minimum value at a pH of 
approximately 6.9. Thus solubility of the drug is reduced in 
intestinal alkaline pH11hence, it was selected in the present 
investigation as a suitable candidate for the design of gastric 
floating drug delivery system for improved retention time 
and bioavailability. The present study is to develop a 
floatable drug delivery system of levofloxacin using hydroxy 
propyl methyl cellulose, carbopol for sustained drug delivery 
and gastric retentive property. Thus the study aims to 
improve the oral bioavailability of the drug and to achieve 
extended retention in the stomach which may result in 
prolonged absorption. 
MATERIALS AND METHODS  
Materials  
Levofloxacin was received as a gift sample from Ajanta 
Pharmaceuticals, Mumbai. Hydroxy Propyl Methylcellulose, 
Magnesium stearate, Sodium bicarbonate, Talc, Carbopol, 
were procured from S. D. Fine Chem. Ltd, Mumbai, India. All 
other solvents and reagents were purchased from Merck 
(Germany) and were of analytical grade. 
Methods 
Determination of λ max of levofloxacin 
The λmax of levofloxacin was determined by analyzing the 
drug solution in double beam ultraviolet spectrophotometer. 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1 N HCl solutions in 10 ml of volumetric flask. The resulted 
solution was 1000µg/ml of strength and from this solution 1 
ml solution was pipette out and transfer into 10 ml capacity 
of volumetric flask and volume was made upto 10 ml with 
0.1 N HCl solutions. This solution was scan at wavelength 
400-200 nm on UV spectrophotometer. The higher 
absorption peak was obtained at 294 nm which was the λmax 
of drug. 
Preparation of calibration curve of levofloxacin 
Previously prepared stock solution (1000 µg/ml of strength) 
of Levofloxacin was use to prepare suitable dilution into 
concentration range of 2-10μg/ml. 0.2, 0.4, 0.6, 0.8 and 1.0 
ml of solution was taken in different volumetric flask having 
10 ml of capacity and dilute upto 10 ml with 0.1 N HCl to 
obtained 2, 4, 6, 8 and 10 μg/ml of solution. The absorbance 
of these solutions was taken at 294nm using UV-
spectrophotometer (Labindia-3000 Plus). Graph between 
absorbance and concentration was plotted followed linearly 
regressed on Microsoft excel.  
Preparation of floating tablets of levofloxacin 
Levofloxacin matrix floating tablets were prepared by direct 
compression method employing sodium bicarbonate as gas-
generating agent. HPMC and Carbopol were used as rate 
controlling polymers. The concentrations of the excipients 
were optimized as showed in table 1. The drug was mixed 
with the rate retarding polymers and other excipients in 
ascending order of their weights. The powder mix was 
blended for 20 min to have uniform distribution of drug in 
the formulation. Then magnesium Stearate and Talc were 
added. About 450 mg of the powder mix was weighed 
accurately and fed into the die and compressed using 10 mm 
round surface punches12. The composition of formulation 
was given in table 1. 
 
Table 1Composition of SR matrix floating tablet of levofloxacin 
Excipients(mg) F1 F2 F3 F4 F5 F6 
Levofloxacin 250 250 250 250 250 250 
HPMC K 4 80 90 100 80 90 100 
Carbopol 20 20 20 30 30 30 
NaHCO3 15 15 15 15 15 15 
Mg(C18H35O2)2 15 15 15 15 15 15 
Talc 15 15 15 15 15 15 
Lactose 55 45 35 45 35 25 
Total Weight 450 450 450 450 450 450 
 
Evaluation of levofloxacin floating matrix tablets 
Pre-compression parameters 
Angle of repose 
The angle of repose of blends was determined by the funnel 
method. The accurately weighed blend was taken in the 
funnel. The height of the funnel was adjusted in such a way 
that the tip of the funnel just touched the apex of the heap of 
the blend. The blend was allowed to flow from the funnel on 
the surface. The diameter and height of the heap formed 
from the blend were measured. The angle of repose was 
calculated using the following formula13. 
Tan Ѳ= h/r 
Where, “h” is the height of the heap and “r” is the radius of 
the heap of granules. 
Bulk density (BD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced in to a measuring cylinder. The volume occupied 
by the powder was measured which gave bulk volume. The 
BD of powder blends was determined using the following 
formula14. 
Bulk density = Total weight of powder/Total volume of 
powder 
Tapped bulk density (TBD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced into a measuring cylinder. The measuring 
cylinder was tapped until no further change in volume was 
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noted which gave the tapped volume. The TBD of powder 
blends was determined using the following formula15. 
TBD = Total weight of powder/Total volume of tapped 
powder 
Carr’s compressibility index 
The Carr’s compressibility index was calculated from bulk 
density (BD) and tapped density of the blend. A quantity of 2 
g of blend from each formulation, filled into a 10 ml of 
measuring cylinder. Initial bulk volume was measured, and 
cylinder was allowed to tap from the height of 2.5 cm. The 
tapped frequency was 25 ± 2/min to measure the tapped 
volume of the blend. The BD and tapped density were 
calculated by using the bulk volume and tapped volume. 
Carr’s compressibility index was calculated using the 
following formula16,17. 
Carr’s compressibility index (%) = [(Tapped density-Bulk 
density) ×100]/Tapped density 
Hausner’s ratio 
It is the measurement of frictional resistance of the drug. The 
ideal range should be 1.2-1.5, it was determined by the ratio 
of tapped density and bulk density. 
HR = Tapped Density/ Bulk Density 
Post-compression parameters 
Shape of tablet 
Directly compressed tablets were examined under the 
magnified lens for the shape of the tablet. 
Thickness 
Twenty tablets from the representative sample were 
randomly taken and individual tablet thickness was 
measured by using digital vernier caliper18. 
Hardness 
Tablet hardness was measured by using Monsanto hardness 
tester. From each batch six tablets were measured for the 
hardness and average of six values was noted along with 
standard deviations. 
Friability test 
From each batch, ten tablets were accurately weighed and 
placed in the friability test apparatus (Roche friabilator). 
Apparatus was operated at 25 rpm for 4 minutes and tablets 
were observed while rotating. The tablets were then taken 
after 100 rotations, de dusted and reweighed. The friability 
was calculated as the percentage weight loss. 
% friability was calculated as follows 
% Friability = (W1 – W2) x 100/W1 
Where W1 = Initial weight of the 10 tablets, W2 = Final 
weight of the 10 tablets after testing. 
Friability values below 0.5-1% are generally acceptable [19]. 
Weight variation test 
To study weight variation individual weights (WI) of 20 
tablets from each formulation were noted using electronic 
balance. Their average weight (WA) was calculated. Percent 
weight variation was calculated as follows. Average weights 
of the tablets along with standard deviation values were 
calculated. 
 
Swelling index  
Swelling study of individual polymers and combinations was 
carried out using eight-stage USP type 1 (basket) Dissolution 
Test Apparatus (Lab India, DS 8000) at 50 rpm, and 0.1 N HCl 
was used as medium, and the temperature was maintained at 
37 ± 0.5°C. Weight of individual tablet was taken prior to the 
swelling study (W1). The tablet was kept in a basket. The 
weight of tablet was taken at time interval of 2, 4, 8, 12 hours 
(W2). Percent hydration (swelling index) was calculated as 
shown in Table using the following formula: 
Swelling index = (W2 - W1) × 100/W2, 
Where W1 is the initial weight of tablet and W2 is the weight 
of hydrated tablet 
Drug content  
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 10mg of drug was 
transferred to 10ml standard flask. The powder was 
dissolved in 5 ml of 0.1 N HCl and made up to volume with of 
0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and for drug content by UV 
spectrophotometer at λ max of 294nm using of 0.1 N HCl as 
blank. 
Dissolution rate studies 
In vitro drug release of the sample was done using USP-type 
II dissolution apparatus (Paddle type). The dissolution 
medium, 900 ml 0.1N HCl was set into the dissolution flask 
maintaining the temperature of 37±0.50C and rpm of 75. One 
levofloxacin tablet was set in every container of dissolution 
apparatus. The mechanical assembly was permitted to keep 
running for 10 hours. Sample measuring 5 ml were pulled 
back after each 1 hour up to 2 hours using 10ml pipette. The 
new disintegration medium (370C) was supplanted each time 
with a similar amount of the sample and takes the 
absorbance at 294.0 nm using spectroscopy. 
Kinetic analysis of dissolution data 
To analyze the in vitro release data various kinetic models 
were used to describe the release kinetics. The zero order 
rate Eq. (1) describes the systems where the drug release 
rate is independent of its concentration. The first order Eq. 
(2) describes the release from system where release rate is 
concentration dependent. Higuchi (1963) described the 
release of drugs from insoluble matrix as a square root of 
time dependent process based on Fickian diffusion Eq. (3). 
The Hixson-Crowell cube root law Eq. (4) describes the 
release from systems where there is a change in surface area 
and diameter of particles or tablets. 
C = K0 t      (1) 
Where, K0 is zero-order rate constant expressed in units of 
concentration/time and t is the time. 
LogC = LogC0 - K1 t / 2.303    (2) 
Where, C0 is the initial concentration of drug and K1 is first 
order constant. 
Q = KHt1/2     (3) 
Where, KH is the constant reflecting the design variables of 
the system. 
Q01/3 – Qt1/3 = KHC t   (4) 
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Where, Qt is the amount of drug remained in time t, Q0 is the 
initial amount of the drug in tablet and KHC is the rate 
constant for Hixson-Crowell rate equation. 
The following plots were made using the in-vitro drug 
release data 
Cumulative % drug release vs. time (Zero order kinetic 
model); Log cumulative of % drug remaining vs. time (First 
order kinetic model); Cumulative % drug release vs. square 
root of time 
(Higuchi model); and cube root of initial concentration minus 
the cube root of percentage of drug remaining in the matrix 
vs. time (Hixson-Crowell cube root law) 20. 
RESULTS AND DISCUSSION 
λ max of levofloxacin  was found to be 294 nm by using U.V. 
spectrophotometer ((Labindia-3000 Plus)) in linearity range 
2-10 µg/ml Fig.1. 
Tablet powder blend was subjected to various pre-
compression parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density of all the formulations was found to be in 
the range of 0.428 to 0.439 (gm/ml) showing that the 
powder has good flow properties. The tapped density of all 
the formulations was found to be in the range of 0.531 to 
0.548 showing the powder has good flow properties. The 
compressibility index of all the formulations was found to be 
ranging between 18.704 to 20.438 which show that the 
powder has good flow properties. All the formulations have 
shown the Hauser’s ratio ranging between 1.230 to 1.257 
indicating the powder has good flow properties. 
 
Figure 1 Calibration curve of levofloxacin in 0.1 N HCl at 
294nm 
 
Table 2 Result of pre-compression properties of levofloxacin GR tablets 








F1 0.432 0.539 19.852 1.248 
F2 0.441 0.543 18.785 1.231 
F3 0.436 0.548 20.438 1.257 
F4 0.432 0.536 19.403 1.241 
F5 0.439 0.540 18.704 1.230 
F6 0.428 0.531 19.397 1.241 
 
The results of post-compression parameters such as the 
uniformity of weight, hardness, thickness, friability, swelling 
index and disintegration time of the tablets are given in 
Table 3. All the tablets of different batches complied with the 
official requirements of uniformity of weight. The hardness 
of the tablets ranged from 5.1±0.3 to 5.6±0.1 kg/cm2 and the 
friability values were less than 0.9% indicating that the 
matrix tablets were compact and hard. The thickness of the 
tablets ranged from 3.21 to 3.45 mm. All the formulations 
satisfied the content of the drug as they contained 98.78 to 
99.56 % of levofloxacin and good uniformity in drug content 
was observed. Thus all the physical attributes of the 
prepared tablets were found be practically within control.
 
Table 3 Results of post compression properties of levofloxacin FGR tablets 








Drug content (%) 
n=3 
F1 3.25 5.2±0.2 445±5 0.898±0.025 99.22±0.022 
F2 3.26 5.4±0.2 455±4 0.852±0.023 98.89±0.021 
F3 3.45 5.6±0.1 450±6 0.987±0.014 99.56±0.026 
F4 3.25 5.5±0.3 452±5 0.569±0.015 99.25±0.041 
F5 3.22 5.2±0.2 442±4 0.852±0.021 98.78±0.032 
F6 3.21 5.1±0.3 440±3 0.745±0.015 99.12±0.025 
 
Swelling study of individual polymers and combinations was 
carried out using eight-stage USP type 1 (basket) Dissolution 
Test Apparatus (Lab India, DS 8000) at 50 rpm, and 0.1 N 
HCl was used as medium, and the temperature was 




Table 4 Results of swelling index of levofloxacin matrix 
tablets 
F. Code % Swelling Index 
2 hrs. 4 hrs. 8hrs. 12hrs. 
F1 22.36 43.56 63.25 73.25 
F2 24.36 44.58 68.89 75.65 
F3 23.45 43.36 65.52 74.58 
F4 28.89 54.57 69.98 79.85 
F5 29.45 55.45 70.23 80.21 
F6 26.45 56.74 72.45 78.25 
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The tablets were evaluated for in vitro dissolution studies in 
Phosphate buffer 0.1N HCl for 12 hrs. The results of the 
optimized formulation F4 showed maximum drug release i.e. 
98.78 % at the end of 12 hrs. The results of release studies of 
formulations F4 was shown in Table 5 & Fig 2. The in vitro 
drug release data of the optimized formulation F4 was 
subjected to goodness of fit test by linear regression analysis 
according to zero order, first order kinetic equation, 
Higuchi’s and Korsmeyer’s models in order to determine the 
mechanism of drug release. When the regression coefficient 
values of were compared, it was observed that ‘r’ values of 
first order was maximum i.e. 0.989 hence indicating drug 
release from formulations was found to follow first order 
release kinetics Table 6 & Fig 3-6. 
  
Table 5  In-vitro drug release study of GRF tablets 
Time % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 F6 
0.5 33.25 32.25 30.14 25.56 20.36 18.56 
1 45.56 40.23 39.98 32.25 26.65 22.25 
1.5 65.56 60.58 59.88 46.69 40.23 39.98 
2 88.89 79.98 78.89 58.89 51.12 49.98 
3 98.89 87.52 85.56 69.98 60.23 55.56 
4 -  93.32 92.23 76.12 71.45 69.78 
6  - 98.85 99.12 88.56 79.98 78.89 
8  -  -  - 92.23 86.65 83.32 
12  -  -  - 98.78 90.12 89.98 
 
 
Figure 2 In-vitro drug release study of GRF tablets 
Table 6 Regression analysis data of levofloxacin floating matrix tablets 
Batch 
Zero Order First Order 
Higuchi Korsmeyer-
Peppas 
r² r² r² r² 
F4 0.788 0.989 0.916 0.946 
 
 
Figure 3 Zero order release kinetics  
 
Figure 4 First order release kinetics  
 
Figure 5 Higuchi release kinetics  
 
Figure 6 Korsmeyer-Peppas release kinetics 
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CONCLUSION  
Gastro-retentive controlled drug delivery system of 
levofloxacin was prepared to increase the therapeutic effect 
of the drug by releasing the drug at the proximal part of the 
small intestine. Levofloxacin is used in eradication of 
Helicobacter Pylori and other bacterial infections. 
Levofloxacin floating tablets were prepared using of 
carbopol and hydroxy propyl methyl cellulose in various 
ratios by direct compression technique employing sodium 
bicarbonate as gas-generating agent. According to the above 
results, formulation F4 offered best controlled release along 
total floating time of 12 h and in-vitro drug release of 98.78% 
at the end of 12 h. 
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